BiomX lands on NYSE American through SPAC merger Chong Kun Dang Pharmaceutical and Handok invested in the company
Translated by Kim So-in 공개 2019-11-25 08:00:00
이 기사는 2019년 11월 25일 08:00 thebell 에 표출된 기사입니다.
Israeli microbiome company BiomX, which received investments from Chong Kun Dang Pharmaceutical and Handok last year, made its trading debut on the NYSE American stock exchange late October.According to industry sources on November 20, shares of BiomX began trading on the NYSE American through a merger with a special purpose acquisition company (SPAC). The NYSE American is the third largest stock exchange in the U.S., after the New York Stock Exchange and the Nasdaq.
Chong Kun Dang acquired 2.9 percent stake in BiomX for 2.8 billion won in a Series B funding round last year. Based on this amount, the enterprise value of BiomX is estimated at 100 billion won. Handok also invested 2.3 billion won in BiomX's convertible preferred stocks. Chong Kun Dang and Handok said that they "invested in the company because BiomX owns superior microbiome technology."
Chardan Capital Markets established its SPAC, Chardan Healthcare Acquisition (CHAC), in July 16 to merger with BioX. CHAC announced the closing of its merger with BiomX late last month. At closing, CHAC retained 70 million dollar in its trust account. The 60 million dollar worth shares of the combined company went public on the NYSE American stock exchange on October 29, 2019.
In connection with the amendment, investors have committed or are expected to commit to an additional purchase of five million dollar of CHAC shares. Cornix Advisors, an affiliate of Chardan, has entered into a securities purchase agreement with a current shareholder of CHAC to purchase two million dollar of CHAC shares at 10.35 dollar per share. Current shareholders of BiomX entered into similar share purchase agreements for three million dollar of CHAC shares, also at 10.35 dollar per share. Chong Kun Dang is expected to have purchased CHAC shares following the approval by the company's board of directors in July.
With BiomX going public through the SPAC merger, investors in Series B funding round may anticipate some profit-taking. BiomX raised 32 million dollar in its Series B funding round. Industry watchers expect that investors in Series B funding round won't be able to exit right away due to a six month lock-up period after the listing. "Even after the lock-up period expires in five months, investors in Series B funding are expected to wait and see how the company's R&D goes for higher returns," said an industry source.
Before the merger, the enterprise value of BiomX was expected to increase to 265 million dollar. The company has a market capitalization of 171 million dollar as of November 19.
OrbiMed, RTW Investment, SBI Japan - Israel Innovation Fund, Johnson & Johnson Innovation -JJDC, and Takeda Ventures also invested in BiomX.
BiomX is a microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as IBD, PSC, and cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.
(By reporter Oh Chan-mi)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
best clicks
최신뉴스 in 전체기사
-
- 소프트아이텍, 국가암데이터센터 운영관리 사업 수주
- 대동, '2024 오늘과 내일의 농업' 이벤트 진행
- [ETF 위클리]중국 회복 기대감, 차이나항셍테크 ETF '불기둥'
- 민희진 보유 어도어 지분, 하이브 콜옵션 행사할까
- [IB 풍향계]'전통강자' NH·한투 위축…IPO 새 판 짜여진다
- [IB 풍향계]미래에셋, IPO 순위경쟁 '가속화'
- [Korean Paper]'역대급' 발행에도…"투자자 피로도 없다"
- [Korean Paper]1년만에 돌아온 해진공, '정기 이슈어' 자리매김
- [IPO 모니터]속도 높이는 DN솔루션즈, '초대형' 주관사단 꾸렸다
- [IB 풍향계]'DN솔루션즈 파트너' 삼성증권 ECM1팀 빛났다